Luspatercept for Lower Risk MDS
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 40 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Tags
- Erythroid Maturation Agent (EMA), Red Blood Cell Stimulant, Growth Factor
- Trial Type
- Supportive
- Last Update
- 4 weeks ago
- SparkCures ID
- 1845
- NCT Identifier
- NCT06113302
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.